Recent advances in ophthalmic preparations : Ocular barriers, dosage forms and routes of administration
Copyright © 2021 Elsevier B.V. All rights reserved..
The human eye is a complex organ with unique anatomy and physiology that restricts the delivery of drugs to target ocular tissues/sites. Recent advances in the field of pharmacy, biotechnology and material science have led to development of novel ophthalmic dosage forms which can provide sustained drug delivery, reduce dosing frequency and improve the ocular bioavailability of drugs. This review highlights the different anatomical and physiological factors which affect ocular bioavailability of drugs and explores advancements from 2016 to 2020 in various ophthalmic preparations. Different routes of drug administration such as topical, intravitreal, intraocular, juxtascleral, subconjunctival, intracameral and retrobulbar are discussed with their advances and limitations.
| Errataetall: |
ErratumIn: Int J Pharm. 2022 Mar 25;616:121583. - PMID 35227537 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:608 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 608(2021) vom: 25. Okt., Seite 121105 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maulvi, Furqan A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug administration |
|---|
| Anmerkungen: |
Date Completed 12.10.2021 Date Revised 01.03.2022 published: Print-Electronic ErratumIn: Int J Pharm. 2022 Mar 25;616:121583. - PMID 35227537 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2021.121105 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33079194X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33079194X | ||
| 003 | DE-627 | ||
| 005 | 20231225212040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2021.121105 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM33079194X | ||
| 035 | |a (NLM)34537269 | ||
| 035 | |a (PII)S0378-5173(21)00911-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maulvi, Furqan A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent advances in ophthalmic preparations |b Ocular barriers, dosage forms and routes of administration |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.10.2021 | ||
| 500 | |a Date Revised 01.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Int J Pharm. 2022 Mar 25;616:121583. - PMID 35227537 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a The human eye is a complex organ with unique anatomy and physiology that restricts the delivery of drugs to target ocular tissues/sites. Recent advances in the field of pharmacy, biotechnology and material science have led to development of novel ophthalmic dosage forms which can provide sustained drug delivery, reduce dosing frequency and improve the ocular bioavailability of drugs. This review highlights the different anatomical and physiological factors which affect ocular bioavailability of drugs and explores advancements from 2016 to 2020 in various ophthalmic preparations. Different routes of drug administration such as topical, intravitreal, intraocular, juxtascleral, subconjunctival, intracameral and retrobulbar are discussed with their advances and limitations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drug administration | |
| 650 | 4 | |a Ocular barriers | |
| 650 | 4 | |a Ophthalmic preparations | |
| 650 | 7 | |a Ophthalmic Solutions |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Shetty, Kiran H |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Ditixa T |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Dinesh O |e verfasserin |4 aut | |
| 700 | 1 | |a Willcox, Mark D P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 608(2021) vom: 25. Okt., Seite 121105 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:608 |g year:2021 |g day:25 |g month:10 |g pages:121105 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2021.121105 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 608 |j 2021 |b 25 |c 10 |h 121105 | ||